États-Unis · Plateformes & données · Benzinga

Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market

Publié par Benzinga · États-Unis il y a 22 min

Résumé détaillé

Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its…

Lire l'article complet sur Benzinga Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.benzinga.com)

Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market

Résumé détaillé

À lire aussi

The 2027 401(k) limits are here. See how much more you can save next year.

Democrats Sweep Congress: What History Says Comes Next for Stocks

Sumitomo Mitsui Financial GAAP EPS of ¥232.59, total operating income of ¥1.43B

Chicago Fed's Goolsbee says central bank 'has definitely got work to do' on inflation

Wolverine World Wide stock hits 52-week high at 23.85 USD

Global Defense Tactical Communication Market Report 2026: Capitalize on 6.8% CAGR Through 2030

Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market

Résumé détaillé

Partager

À lire aussi

The 2027 401(k) limits are here. See how much more you can save next year.

Democrats Sweep Congress: What History Says Comes Next for Stocks

Sumitomo Mitsui Financial GAAP EPS of ¥232.59, total operating income of ¥1.43B

Chicago Fed's Goolsbee says central bank 'has definitely got work to do' on inflation

Wolverine World Wide stock hits 52-week high at 23.85 USD

Global Defense Tactical Communication Market Report 2026: Capitalize on 6.8% CAGR Through 2030